戻る Agenda
Session 6: IMPD-Q Only Trials : Operational and Disclosure Aspects
Session Chair(s)
Scott Feiner
Senior Manager, Trial Disclosure
AbbVie, United States
Ruediger Pankow, DRSC
Clinical Trial Regulatory Consultant | CTIS SME
Independent Consultant, Germany
Session 6: IMPD-Q Only Trials : Operational and Disclosure Aspects
Speaker(s)
Opening: Why does IMPD-Q only application exists?
Scott Feiner
AbbVie, United States
Senior Manager, Trial Disclosure
IMPD-Q Owner Experience
Scott Feiner
AbbVie, United States
Senior Manager, Trial Disclosure
IMPD-Q Owner Experience
Raquel Vaquer Pérez
Bristol-Myers Squibb, Belgium
EU CTR implementation lead
Academia Perspective
Stéphanie Kromar
European Organisation for Research and Treatment of Cancer (EORTC) , Belgium
Senior Regulatory Affairs Manager
Member State Experience
Jan Willem Kleinovink
Central Committee on Research Involving Human Subjects (CCMO), Netherlands
Scientific staff / Validation team lead / CTIS Support
Contributing Panelist
Marianne Lunzer, DrMed
AGES, Austria
Assessor, Dept of Clinical Trials, Federal Office for Safety in Health Care